Clonal T-cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA-A*0206

Journal of Orthopaedic Research

Volumn 26, Issue 2, 2008, Pages 271-278

  Kimura, Shigeharu ^a   Kozakai, Yuriko ^a   Kawaguchi, Satoshi ^a   Tsukahara, Tomohide ^a   Ida, Kazunori ^a   Murase, Masaki ^a   Matsumura, Tadaki ^a   Kaya, Mitunori ^a   Torigoe, Toshihiko ^a   Wada, Takuro ^a   Sato, Noriyuki ^a   Yamashita, Toshihiko ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocyte; Human leukocyte antigen (HLA) class I; Immunotherapy; Malignant fibrous histiocytoma; Tumor associated antigen

Indexed keywords

COMPLEMENTARY DNA; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; AUTOANTIGEN; HLA A ANTIGEN; HLA A*0206 ANTIGEN; HLA ANTIGEN; HLA-A*0206 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER TISSUE; CASE REPORT; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; GENETIC TRANSFECTION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CLONE; MALIGNANT FIBROUS HISTIOCYTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TISSUE CULTURE; CHEMISTRY; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE; TUMOR CELL LINE;

AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FEMALE; GENOTYPE; HERPESVIRUS 4, HUMAN; HISTIOCYTOMA, MALIGNANT FIBROUS; HLA ANTIGENS; HLA-A ANTIGENS; HUMANS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 38849170614     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20497     Document Type: Article

References (26)

1. Marcove RC, Mike V, Huvos AG, et al. 1973. Vaccine trials for osteogenic sarcoma. A preliminary report. CA Cancer J Clin 23:74-80.
2. Neff JR, Enneking WF. 1975. Adoptive immunotherapy in primary osteosarcoma. An interim report. J Bone Joint Surg [Am] 57:145-148.
3. Geiger J, Hutchinson R, Hohenkirk L, et al. 2000. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356:1163-1165.
4. Dagher R, Long LM, Read EJ, et al. 2002. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38:158-164.
5. Matsuzaki A, Suminoe A, Hattori H, et al. 2002. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 24:220-223.
6. Dillman R, Barth N, Selvan S, et al. 2004. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm 19:581-588.
7. Kawaguchi S, Wada T, Ida K, et al. 2005. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transi Med 3:1.
8. Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915.
9. Kawaguchi S, Wada T, Tsukahara T, et al. 2005. A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transi Med 3:31.
10. Maki RG. 2006. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 18:363-368.
11. Chang CC, Campoli M, Ferrone S. 2003. HLA class I defects in malignant lesions: what have we learned? Keio J Med 52:220-229.
12. Tsukahara T, Kawaguchi S, Torigoe T, et al. 2006. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 97:1374-1380.
13. Dunn GP, Bruce AT, Ikeda H, et al. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998.
14. Schreiber H, Wu TH, Nachman J, Kast WM. 2002. Immunodominance and tumor escape. Semin Cancer Biol 12:25-31.
15. So T, Takenoyama M, Mizukami M, et al. 2005. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 65:5945-5952.
16. Nabeta Y, Kawaguchi S, Sahara H, et al. 2003. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci 8:554-559.
17. Tsukahara T, Kawaguchi S, Ida K, et al. 2006. HLA-restricted specific tumor cytolysis by autologous T lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. J Orthop Res 24:94-101.
18. Zhu X, Belmont HJ, Price-Schiavi S, et al. 2006. Visualization of p53(264-272)/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor. J Immunol 176:3223-3232.
19. Sato Y, Nabeta Y, Tsukahara T, et al. 2002. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 169:1611-1618.
20. Ida K, Kawaguchi S, Sato Y, et al. 2004. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 173:1436-1443.
21. Tsukahara T, Nabeta Y, Kawaguchi S, et al. 2004. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64:5442-5448.
22. Nencioni A, Grunebach F, Patrone F, Brossart P. 2004. Anticancer vaccination strategies. Ann Oncol 15:iv153-iv60.
23. Singh-Jasuja H, Emmerich NP, Rammensee HG. 2004. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 53:187-195.
24. Helman LJ, Meltzer P. 2003. Mechanisms of sarcoma development. Nat Rev Cancer 3:685-694.
25. Matushansky I, Maki RG. 2005. Mechanisms of sarcoma-genesis. Hematol Oncol Clin North Am 19:427-449.
26. el-Deiry WS, Tokino T, Velculescu VE, et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.